Advances in our understanding of the genetic mutations and alterations and resultant expression are leading to the identification of more and more biomarkers to help direct patient management. Biomarker development and applications are being seen in early detection, prognosis, toxicity profiling, predictive, effective monitoring, follow up, etc. IIR’s Collaborative Summit for Oncology brings together a multi-stakeholder view of the current state of biomarker use and how the use of these applications will lead to less toxic care. They will also discuss insights into what you can expect to see in the next 3-5 years to increase positive outcomes and manage costs of oncology.
SESSION SPOTLIGHT: The Use of Screenings, Biomarkers & Diagnostic Testing to Increase Positive Outcomes and Manage Cost of Oncology
Moderator: Paul Howard, Director and Senior Fellow Center for Medical Progress, Manhattan Institute for Policy Research
Panelists:
• William T. McGivney, PhD, Former NCCN CEO, McGivney Global Advisors
• Oscar Puig, Biomarker Lead in Oncology, Translational Clinical Research Center, Roche
• Maurie Markman, MD, Senior Vice President, Clinical Affairs, Cancer Treatment Centers of America
To learn more, download our brochure.
As a reader of the healthcare insights blog, you can use priority code XP1814BLOG to receive 15% off of the standard rate to register. If you have any questions or need any further information, feel free to email kdevery@iirusa.com or visit the webpage.
We look forward to seeing you in June!
Best,
Oncology Management Team
Visit the Oncology Management Webpage
Follow us on Twitter
No comments:
Post a Comment